ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Rhode Island » Pulmonary Disease

Top Pulmonary Disease Prescribers in Rhode Island

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
RONALD GILMAN MD

Pulmonary Disease

11,937

$725K

600
527 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

3%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 58%

$61
Average prescription price

Avg: $140

JAMES MYERS MD

Pulmonary Disease

11,110

$699K

635
548 are 65+

3%
patients receiving schedule two controlled substances

Avg: 1%

5%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 58%

$63
Average prescription price

Avg: $140

MICHAEL BAAKLINI MD

Pulmonary Disease

8,890

$480K

300
201 are 65+

17%
patients receiving schedule two controlled substances

Avg: 1%

19%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 58%

$54
Average prescription price

Avg: $140

THOMAS RAIMONDO

Pulmonary Disease

8,509

$905K

497
401 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

4%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

39%
prescriptions for brand name drugs

Avg: 58%

$106
Average prescription price

Avg: $140

WALTER DONAT M.D.

Pulmonary Disease

6,018

$962K

587
510 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

60%
prescriptions for brand name drugs

Avg: 58%

$160
Average prescription price

Avg: $140

STEPHEN MATARESE DO

Pulmonary Disease

5,597

$1.02M

402
334 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

3%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

48%
prescriptions for brand name drugs

Avg: 58%

$182
Average prescription price

Avg: $140

RAFFI CALIKYAN M.D.

Pulmonary Disease

5,146

$301K

486
378 are 65+

5%
patients receiving schedule two controlled substances

Avg: 1%

7%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 58%

$59
Average prescription price

Avg: $140

WILLIAM CORRAO M.D.

Pulmonary Disease

4,144

$684K

509
445 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

61%
prescriptions for brand name drugs

Avg: 58%

$165
Average prescription price

Avg: $140

CHARLES SHERMAN MD

Pulmonary Disease

2,942

$386K

379
317 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

58%
prescriptions for brand name drugs

Avg: 58%

$131
Average prescription price

Avg: $140

JOHN LADETTO M.D.

Pulmonary Disease

2,759

$730K

344
278 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

75%
prescriptions for brand name drugs

Avg: 58%

$265
Average prescription price

Avg: $140

NEIL LABOVE M.D.

Pulmonary Disease

2,411

$417K

274
206 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

75%
prescriptions for brand name drugs

Avg: 58%

$173
Average prescription price

Avg: $140

MICHAEL POMERANTZ MD

Pulmonary Disease

2,160

$246K

330
271 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

54%
prescriptions for brand name drugs

Avg: 58%

$114
Average prescription price

Avg: $140

JOHN PELLA MD

Pulmonary Disease

2,061

$283K

351
294 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

67%
prescriptions for brand name drugs

Avg: 58%

$137
Average prescription price

Avg: $140

PETER KARCZMAR MD

Pulmonary Disease

1,987

$254K

218
179 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

47%
prescriptions for brand name drugs

Avg: 58%

$128
Average prescription price

Avg: $140

ANNE HEBERT MD

Pulmonary Disease

1,862

$245K

234
200 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

55%
prescriptions for brand name drugs

Avg: 58%

$132
Average prescription price

Avg: $140

NIALL DUHIG MD

Pulmonary Disease

1,724

$368K

250
217 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

77%
prescriptions for brand name drugs

Avg: 58%

$213
Average prescription price

Avg: $140

TILAK VERMA MD, MBA

Pulmonary Disease

1,544

$261K

230
192 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

87%
prescriptions for brand name drugs

Avg: 58%

$169
Average prescription price

Avg: $140

MOHAMMAD KHAMIEES MD

Pulmonary Disease

1,424

$405K

364
191 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

82%
prescriptions for brand name drugs

Avg: 58%

$284
Average prescription price

Avg: $140

MICHAEL STANCHINA

Pulmonary Disease

1,267

$290K

234
174 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

64%
prescriptions for brand name drugs

Avg: 58%

$229
Average prescription price

Avg: $140

DOUGLAS MARTIN MD

Pulmonary Disease

1,245

$207K

185
139 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

78%
prescriptions for brand name drugs

Avg: 58%

$166
Average prescription price

Avg: $140

MOHAMMAD KHAN MD

Pulmonary Disease

1,194

$177K

153
122 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

64%
prescriptions for brand name drugs

Avg: 58%

$148
Average prescription price

Avg: $140

ALICE BONITATI MD

Pulmonary Disease

1,093

$254K

173
100 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

59%
prescriptions for brand name drugs

Avg: 58%

$232
Average prescription price

Avg: $140

RICHARD MILLMAN MD

Pulmonary Disease

942

$259K

142
91 are 65+

11%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

33%
prescriptions for brand name drugs

Avg: 58%

$275
Average prescription price

Avg: $140

MICHAEL BLUNDIN MD

Pulmonary Disease

906

$137K

198
163 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

71%
prescriptions for brand name drugs

Avg: 58%

$151
Average prescription price

Avg: $140

MOHAMMAD YASSIN HMADEH M.D

Pulmonary Disease

856

$238K

123
90 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

81%
prescriptions for brand name drugs

Avg: 58%

$278
Average prescription price

Avg: $140

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank